menu
    • menu
    [{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Parexel Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ Synairgen"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Foralumab","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Parexel Biotech \/ Tiziana Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Biotech \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ InDex Pharmaceuticals"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Pharmaxis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hard Gelation Capsule","sponsorNew":"Parexel Biotech \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Biotech \/ Parexel"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Parexel Biotech \/ n-Lorem","highestDevelopmentStatusID":"2","companyTruncated":"Parexel Biotech \/ n-Lorem"}]

    Find Clinical Drug Pipeline Developments & Deals by Parexel Biotech

    Menu

    Parexel Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Parexel and n-Lorem Foundation Partner to Support Development of New Investigational Therapies for Nano-rare P...

                            Details : Partnership will support the n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 23, 2022

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PXS-5505

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Pharmaxis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

                            Details : The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.

                            Brand Name : PXS-5505

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2021

                            Lead Product(s) : PXS-5505

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Pharmaxis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cobitolimod

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : InDex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InDex Pharmaceuticals Enters Agreement with Parexel Biotech for Phase III Clinical Study of Cobitolimod for Ul...

                            Details : CONCLUDE is a randomised, double-blind, placebo-controlled, global phase III study to evaluate cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.

                            Brand Name : Kappaproct

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 30, 2021

                            Lead Product(s) : Cobitolimod

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : InDex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Tiziana Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tiziana Life Sciences Announces Collaboration with Parexel Biotech to Conduct Phase 1b/2 Clinical Trial in Pat...

                            Details : This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.

                            Brand Name : TZLS-401

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 11, 2020

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Tiziana Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Parexel Biotech

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Parexel Biotech Collaborates with Synairgen on Pivotal Phase III Trial for Study of Inhaled COVID-19 Treatment

                            Details : Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.

                            Brand Name : SNG001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 20, 2020

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth